Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial - Summary - MDSpire

Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial

  • By

  • Thierry Lebret

  • Xavier Paoletti

  • Geraldine Pignot

  • Mathieu Roumiguié

  • Marc Colombel

  • Laurent Savareux

  • Grégory Verhoest

  • Laurent Guy

  • Jérome Rigaud

  • Stéphane De Vergie

  • Grégoire Poinas

  • Stéphane Droupy

  • François Kleinclauss

  • Monique Courtade-Saïdi

  • Eric Piaton

  • Camelia Radulescu

  • Nathalie Rioux-Leclercq

  • Christine Kandel-Aznar

  • Karine Renaudin

  • Béatrix Cochand-Priollet

  • Yves Allory

  • Sébastien Nivet

  • Morgan Rouprêt

  • July 22, 2023

  • 0 min

Share

Objective:

To assess the diagnostic performance of the VisioCyt® test for detecting bladder cancer (BC) in terms of sensitivity and specificity.

Key Findings:
  • VisioCyt® demonstrated improved sensitivity in detecting both high- and low-grade tumors compared to traditional cytology, with sensitivity rates of X% and Y%.
  • The device provides a noninvasive alternative for bladder cancer diagnosis.
Interpretation:

The VisioCyt® test shows promise as a reliable diagnostic tool for bladder cancer, potentially reducing the need for invasive procedures and improving patient outcomes.

Limitations:
  • The study excluded patients with certain conditions, which may limit generalizability to the broader population.
  • The analysis was blinded to histopathological results, but the absence of pathologist evaluation may affect accuracy.
Conclusion:

The VISIOCYT1 trial supports the use of AI-driven VisioCyt® for enhancing bladder cancer diagnosis, warranting further studies for broader application and exploration of its clinical impact.

Original Source(s)

Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial

  • by Thierry Lebret, Xavier Paoletti, Geraldine Pignot, Mathieu Roumiguié, Marc Colombel, Laurent Savareux, Grégory Verhoest, Laurent Guy, Jérome Rigaud, Stéphane De Vergie, Grégoire Poinas, Stéphane Droupy, François Kleinclauss, Monique Courtade-Saïdi, Eric Piaton, Camelia Radulescu, Nathalie Rioux-Leclercq, Christine Kandel-Aznar, Karine Renaudin, Béatrix Cochand-Priollet, Yves Allory, Sébastien Nivet, Morgan Rouprêt

  • July 22, 2023

Related Content

Illumination matters Part III: Impact of light obstruction on illuminance from flexible ureteroscopes — a comparative PEARLS analysis

Confocal laser endomicroscopy for upper tract urothelial carcinoma: validation of the proposed criteria and proposal of a scoring system for real-time tumor grading

Sharper Imaging, Smarter Tools: Inside the MonacoPro

With its combination of UWF imaging, OCT integration, and intelligent review tools, the MonacoPro represents the next step in comprehensive retinal evaluation. By improving image quality, enhancing diagnostic confidence, and streamlining workflow, the system supports clinicians in delivering more efficient, informed, and patient-centered care.